Seeking Alpha

MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally...

MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally inhaled drug for the potential treatment of acute migraine, has been accepted for filing by the FDA. The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26 action letter and has set a goal date of April 15, 2013 under the prescription drug user fee act.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|